Pharmacogenomics Journal

Papers
(The TQCC of Pharmacogenomics Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study103
Development of an extensive workflow for comprehensive clinical pharmacogenomic profiling: lessons from a pilot study on 100 whole exome sequencing data59
Correction to: A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform37
Plasma concentrations of venetoclax and Pharmacogenetics correlated with drug efficacy in treatment naive leukemia patients: a retrospective study37
STRIPE partners in precision medicine series: provider perspective24
A potential association of SLC2A9 variant rs7442295 with uric acid at baseline and in interaction with iloperidone13
Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study13
Using ChatGPT to predict the future of personalized medicine12
A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care12
Impact of population-specific pharmacogenomic variants on drug dosing in ICU patients12
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients11
Investigating genetic variants for treatment response to selective serotonin reuptake inhibitors in syndromal factors and side effects among patients with depression in Taiwanese Han population11
Effect of CYP2C19 polymorphisms on antidepressant prescription patterns and treatment emergent mania in bipolar disorder10
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration10
Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants10
STRIPE partners in precision medicine series: Patient perspective10
Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients9
Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing9
TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer9
The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?9
Pharmacogenomics to optimise psychotropic prescribing: a survey of mental health professionals’ perceptions, knowledge, and educational needs8
APF2: an improved ensemble method for pharmacogenomic variant effect prediction8
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine8
CYP2C19 point-of-care testing: where are we now and where should we go?8
Knowledge and attitudes of medical and pharmacy students about pharmacogenomics: a systematic review and meta-analysis8
Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppress7
Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications7
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population7
Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients6
Potential of pharmacogenetics in treatment of chronic inflammatory diseases – a danish report overview from 2000 – 20246
Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects6
Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)6
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China6
Genetic markers of early response to lurasidone in acute schizophrenia6
Network pharmacology prediction, molecular docking and in vitro experiment explored the potential mechanism of Gaoyuan’an capsule in improving hypoxia tolerance6
Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation6
0.022559881210327